BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have received an average rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $253.69.

BGNE has been the topic of a number of analyst reports. StockNews.com began coverage on shares of BeiGene in a research note on Sunday, January 19th. They issued a “hold” rating on the stock. TD Cowen upped their price target on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. increased their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Finally, Morgan Stanley reissued an “overweight” rating and issued a $300.00 price objective on shares of BeiGene in a research note on Tuesday, December 3rd.

BeiGene Stock Performance

The stock’s 50 day moving average is $194.32 and its 200-day moving average is $188.98. BeiGene has a twelve month low of $126.97 and a twelve month high of $248.16. The firm has a market cap of $18.03 billion, a P/E ratio of -22.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s revenue was up 28.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Equities research analysts predict that BeiGene will post -5.64 EPS for the current fiscal year.

Insider Activity at BeiGene

In related news, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the sale, the director now owns 791,493 shares of the company’s stock, valued at $148,222,894.11. This trade represents a 56.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,119,245 shares of company stock valued at $209,700,084 in the last three months. Corporate insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in shares of BeiGene by 118.9% in the second quarter. Dimensional Fund Advisors LP now owns 11,499 shares of the company’s stock worth $1,649,000 after purchasing an additional 6,246 shares during the last quarter. Sei Investments Co. raised its position in BeiGene by 3.6% in the 2nd quarter. Sei Investments Co. now owns 24,248 shares of the company’s stock valued at $3,459,000 after buying an additional 848 shares during the last quarter. Point72 Asset Management L.P. bought a new position in BeiGene during the 2nd quarter valued at $54,412,000. Squarepoint Ops LLC boosted its holdings in BeiGene by 2.5% during the 2nd quarter. Squarepoint Ops LLC now owns 72,055 shares of the company’s stock worth $10,280,000 after acquiring an additional 1,743 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of BeiGene by 33.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 110,000 shares of the company’s stock worth $15,694,000 after acquiring an additional 27,857 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.